A new year brings exciting new developments in diabetes management.

For the first time, people in the United States who use Abbott’s world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology to manage their diabetes can experience the therapeutic benefits of an automated insulin delivery (AID) system that helps predict and prevent high and low blood sugar.

That’s because Abbott’s new FreeStyle Libre 2 Plus sensor integrates with the t:slim X2 insulin pump from Tandem Diabetes Care Inc.

The FreeStyle Libre 2 Plus sensor, which is the modified FreeStyle Libre 2 sensor cleared in 2023 by the Food & Drug Administration for use with AID systems, is the first and only CGM available in the United States with a wear time of 15 days¹ for both adults and children, thereby offering greater convenience and cost savings to people with diabetes.

This is the latest in a series of partnerships aimed at improving and streamlining diabetes care. Last year Abbott integrated its FreeStyle Libre 3 sensor with CamDiab’s CamAPS FX mobile app and Ypsomed’s mylife YpsoPump to implement an AID system in Europe. 

The broader reach resulting from these partnerships will strengthen Abbott’s position in the CGM market and expand opportunities for growth.

The FreeStyle Libre 2 Plus sensor connects wirelessly to the pump and automatically sends it glucose readings every minute². Users can see their glucose data on the pump and in the t:connect app³. The t:slim X2 pump with Control-IQ technology predicts glucose levels 30 minutes into the future, automatically adjusting insulin delivery every five minutes based on CGM readings and delivering automatic correction boluses (up to one per hour) to help prevent hyperglycemia⁴.

Abbott is working with several insulin pump and smart insulin pen manufacturers to integrate their systems with FreeStyle Libre technology as soon as possible.

Click here for more information on how Abbott’s FreeStyle Libre technology plays an essential role in powering AID systems that take the guesswork out of managing diabetes.

References

¹Based on patient applied sensors currently on the market in the U.S.
² FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump. Glucose data is visualized on the t:connect mobile app and t:slim X2 insulin pump.
³ The information on the t:connect mobile app display may not be identical to the current status of your pump. Wireless uploads from the t:connect mobile app to the cloud-based t:connect web application require a compatible phone and an internet or wireless data connection. Uploads to the t:connect web application do not take place in real time and should not be relied upon by healthcare providers or caregivers for remote patient monitoring. Standard carrier data rates may apply.
⁴If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.